Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Technology
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Foment shows how the leadership of a new generation of female innovators is already a reality at # MWC21Foment del Treball

Foment shows how the leadership of a new generation of female innovators is already a reality at # MWC21

En el marc de la celebració dels seus 250 anys i de la seva col·laboració amb la Fundació Mobile…
Read more
Innovation & Scalability for the new generations

Innovation & Scalability for the new generations

On the occasion of the Mobile World Congress Barcelona & 4YFN, Gate2Brain will be participating tomorrow…
Read more
round table at 2021 Worldwide Congress Barcelona & 4YFN

On the occasion of the Mobile World Congress Barcelona & 4YFN, Gate2Brain will participate in the round table session organized by Foment del Treball, on “Innovation & Scalability for the new generations”

Foment intensifica la seva presència al MWC i al 4YFN 2021La patronal organitza una jornada en un…
Read more
Entrepreneurship for Life Sciences and Healthcare Startups Spring Cohort 2021

Gate2Brain attended from March to June the UCFS’s Entrepreneurship for Life Sciences and Healthcare Startups Spring Cohort 2021

Gate2Brain attended from March to June the Entrepreneurship for Life Sciences and Healthcare Startups…
Read more
Gate2Brain selected to form the Spanish Delegation for AnglonordiScience Conference 2021

Gate2Brain selected to form the Spanish Delegation for Anglonordic Life Science Conference 2021

Anglonordic is the only life science conference in the UK that is exclusively for European investors…
Read more

Gate2Brain along with other 26 Catalan startups has been awarded with financial support by Startup Capital d’Acció 2020

La línia Startup Capital d’ACCIÓ 2020, amb un 25% més de pressupost, ha beneficiat 27 empreses,…
Read more
Gate2Brain will be attending Bio€quity Europe 2021

Gate2Brain will be attending Bio€quity Europe 2021

Gate2Brain will be attending Bio€quity Europe 2021. Bio€quity is Europe’s premier international…
Read more
Gate2Brain

Gate2Brain, a new member of CataloniaBio & HealthTech

Gate2Brain has recently become member of CataloniaBio & HealthTech. An entity that represents…
Read more

Innovative Training Sessions IDIBGI (Cicle Píndoles d’Innovació IDIBGI)

Organised by IDIBGI (Girona Biomedical Research Institut) Meritxell Teixidó, Gate2Brain’s…
Read more
NEWS & MEDIA

1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social